RegenxBio raises $175.5M follow-on

RegenxBio Inc. (NASDAQ:RGNX) raised $175.5 million through the sale of 2.7 million shares at $65 in a follow-on underwritten by Morgan Stanley, BofA Merrill Lynch, Barclays and Raymond James.

On Wednesday, the company disclosed a treatment-related serious adverse event (SAE) in which a patient was hospitalized with transient, asymptomatic elevated transaminases in a Phase I/II trial of RGX-501 to treat homozygous familial hypercholesterolemia (HoFH). The company previously reported a treatment-related SAE of mild transitory immune system activation accompanied by hypotension and elevated transaminases in the trial (see “RegnexBio Discloses Second Serious AE for Hypercholesterolemia Gene Therapy”)...